-+ 0.00%
-+ 0.00%
-+ 0.00%

BriaCell Says A Patient Achieved Sustained Complete Resolution Of Lung Metastasis In Its Metastatic Breast Cancer Study

Benzinga·07/09/2025 11:32:23
Listen to the news

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer (MBC) treated with Bria-OTS, the Company's personalized off the shelf immunotherapy.

BriaCell's first Bria-OTS study patient, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung metastasis following four doses of BriaCell's Bria-OTS monotherapy. The complete response was first observed at two months (previously reported) and confirmed at four (previously reported) and now six months. The patient has been dosed with 12 cycles of Bria-OTS to date.